Swiss pharma giant Roche Holding AG's RHHBY 2025 results were affected by currency headwinds. Sales totaled $74.4 billion, which missed the Zacks Consensus Estimate of $81.4 billion. Earnings per ...

Pharmaceutical company Eli Lilly (LLY) has announced plans to invest more than $3.5 billion to construct a new manufacturing facility in Pennsylvania's Lehigh Valley. This ...

Novo Nordisk A/S Q3 costs, Q4 savings, and oral Wegovy launch drive EPS upside. Click for this NVO stock update and earnings preview.

As massive capital flows into the life science sector, two distinct, and potentially opposing, strategic directions have ...

Although Amgen does not yet have a GLP-1 drug approved for the market, this situation may change in the future. With a market capitalization of approximately $950 billion, Eli Lilly (LLY) has risen ...

SHANGHAI, Jan 30 (Reuters) - Sciwind Biosciences' type 2 diabetes treatment Xianyida was approved for use in China, the ...

ALLENTOWN - In a big win for Pennsylvania and the Lehigh Valley, Eli Lilly & Co. has announced plans to build a $3.5 billion ...

Eli Lilly CEO Dave Ricks said upcoming Medicare coverage of obesity drugs could be a game-changer for the launch of its experimental weight-loss pill orforglipron, potentially expanding access to ...

BERLIN, Jan 27 (Reuters) - Roche's experimental obesity drug, which works in a similar way to Eli Lilly's Zepbound, produced ...

The plant will help make Lilly's experimental drug called retatrutide, which has shown the highest weight loss seen to date in a late-stage trial.

Roche aims to become a “top three player” in obesity, Teresa Graham, CEO of the group’s Pharma unit, said Thursday during a ...

NVO and VKTX face rising competition and setbacks as investors weigh scale, pipelines and execution risks in the crowded ...